Almost everything on this site concerns GHK-Cu applied to skin. A 2025 paper took a different route entirely: mice with chemically induced colitis were fed the peptide by gavage, and their guts were examined. It is a real, reasonably thorough piece of work, and it is also the sort of study most likely to be misused as a reason to swallow a copper peptide supplement.
This article covers GHK-Cu as a cosmetic ingredient. It is not medical advice, and nothing here has been evaluated by the FDA.
Key Takeaways
- Mice were given 3% dextran sulfate sodium in drinking water for 12 days to induce ulcerative colitis, then treated by daily oral gavage with GHK-Cu at 20 mg/kg or the standard drug 5-ASA at 40 mg/kg [1].
- GHK-Cu reduced weight loss and disease activity, lessened colonic shortening and inflammatory damage, increased goblet cell numbers, and suppressed TNF-alpha, IL-6 and IL-1 beta [1].
- It raised the tight junction proteins ZO-1 and occludin, and network pharmacology plus molecular docking identified SIRT1 as the likely target, acting through the SIRT1/STAT3 pathway [1].
- Silencing STAT3 abolished the healing effect on colonic epithelial cells, which is a real mechanistic test rather than a correlation [1].
- It is a chemically induced model in mice at a pharmacological oral dose. It is not a reason for anyone to take a copper peptide by mouth.
What the Model Is
Dextran sulfate sodium colitis is the workhorse model for inflammatory bowel disease research. DSS in drinking water damages the colonic epithelium and produces weight loss, diarrhoea, bleeding and a shortened, inflamed colon within days. It reproduces the mucosal injury and barrier failure of ulcerative colitis, which is what makes it useful, and it is a chemical insult in a healthy animal rather than the chronic immune-mediated disease people have.
The design was straightforward [1]. Four groups of eight BALB/c mice: control, DSS alone, DSS plus 5-ASA at 40 mg/kg, and DSS plus GHK-Cu at 20 mg/kg. Treatment was daily oral gavage for 14 days, with control and DSS-only groups gavaged with saline so the handling matched. Including 5-ASA, an established first-line drug for ulcerative colitis, as a comparator is a good sign in a study like this.
What They Found
GHK-Cu treated mice lost less weight, scored better on the disease activity index, had less colonic oedema and shortening, and showed less inflammatory damage on histology. Goblet cell numbers, which fall as the mucus layer is destroyed, were higher. The inflammatory cytokines TNF-alpha, IL-6 and IL-1 beta were suppressed [1].
The barrier findings are the more specific ones. Tight junction proteins ZO-1 and occludin, which hold the epithelial sheet sealed, were upregulated. A co-culture of mouse colonic epithelial cells with peritoneal macrophages reproduced this: GHK-Cu helped DSS-damaged epithelial cells heal and raised both tight junction proteins.
The Mechanistic Work Is Better Than Usual
Plenty of papers stop at network pharmacology and molecular docking, computational methods that predict which targets a compound might hit. Those predictions pointed at SIRT1, a deacetylase involved in inflammation and metabolism [1].
The authors then tested it. GHK-Cu raised SIRT1 protein and suppressed phosphorylated STAT3 in colon tissue and in the co-culture. They silenced STAT3 with siRNA, and the effect of GHK-Cu on epithelial healing and on ZO-1 and occludin disappeared, while its suppression of inflammatory cytokines partly survived. They also found reduced RORgamma-t, a marker pointing at fewer Th17 cells.
That combination, a predicted target followed by a knockdown that removes the effect, is a genuine causal test. It says the healing effect runs through STAT3, and that the anti-inflammatory effect probably has additional routes.
Why This Is Not a Reason to Swallow Anything
The dose was 20 mg/kg daily by gavage. Scaled naively to a person, that is a substantial daily dose of a copper-containing compound delivered directly into the stomach.
Copper is not a nutrient with a wide safety margin. It is an essential trace element with a narrow window between adequate and excessive, and chronic excess causes real harm. Any oral copper compound taken outside medical supervision carries that risk, and this study measured nothing about it, since it ran for 14 days in healthy young mice with induced injury.
Induced colitis in a mouse is also not ulcerative colitis in a person. Compounds that improve DSS colitis and then fail in human IBD trials are a long list. Ulcerative colitis is a serious disease with real treatments, and the appropriate response to having it is a gastroenterologist.
The 16-Patient Claim
The paper’s discussion mentions a pilot study of 16 patients with distal inflammatory bowel disease reporting a mean 60% reduction in disease severity after 12 weeks of rectal GHK-Cu, assessed endoscopically, histopathologically and symptomatically, attributed to a 2008 report by Pickart [1].
That deserves flagging rather than repeating. A search of PubMed does not return an indexed publication matching it, and Loren Pickart is the researcher who isolated GHK and has a long-standing commercial interest in copper peptides [2]. An uncontrolled pilot of 16 people, not indexed in the primary biomedical database, reported by the molecule’s principal advocate, is a claim to note and not a result to rely on.
How This Fits the Rest of the Evidence
Read alongside the 2026 finding that GHK-Cu extends lifespan and activates antioxidant pathways in C. elegans [3], a picture emerges of a molecule with real systemic anti-inflammatory and repair-associated activity in animal models across quite different tissues.
That is interesting, and it is also a separate research question from what happens when a cosmetic serum is applied to a face, where the central obstacle remains getting the complex through skin at all [4]. Systemic animal results do not transfer to topical use, in either direction. A peptide that helps a mouse colon when swallowed tells you nothing about wrinkles, and a serum that does something to your skin is not treating your gut.
Frequently Asked Questions
Does GHK-Cu help ulcerative colitis?
There is no evidence in people that would support that. The 2025 study was a chemically induced colitis model in mice, given GHK-Cu by oral gavage at 20 mg/kg for 14 days [1]. Induced colitis in mice is not the same disease as ulcerative colitis in a person.
Was the peptide swallowed in that study?
Yes. The treatment group was gavaged daily with GHK-Cu at 20 mg/kg, alongside a 5-ASA comparison group at 40 mg/kg [1]. That is a deliberate oral dosing protocol, not a skincare exposure.
Should I take a copper peptide supplement for gut health?
No. A mouse model result is not a basis for that, copper has a narrow safe intake range, and swallowing copper compounds without medical supervision risks harm the study says nothing about.
What about the 16-patient study people mention?
The colitis paper’s discussion cites a 2008 pilot of 16 patients with distal inflammatory bowel disease treated rectally, reporting a mean 60% reduction in severity. That report is not indexed in PubMed and is attributed to the peptide’s principal commercial advocate, so it should be treated as an uncontrolled claim rather than evidence.
References
- Mao S, Huang J, Li J, et al. Exploring the Beneficial Effects of GHK-Cu on an Experimental Model of Colitis and the Underlying Mechanisms. Frontiers in Pharmacology (2025). PMID 40672369
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences (2018). PMID 29986520 (authors affiliated with Skin Biology, a company that sells copper-peptide products)
- Wen H, Zhao K, Luo X, et al. The GHK-Cu Delays Aging in Caenorhabditis elegans via Coordinated Regulation of Mitochondrial Function and Activation of DAF-16/SKN-1 Pathways. Biogerontology (2026). PMID 42084774
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective. BioImpacts (2025). PMID 39963574
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical or dermatological advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
